Annalee Armstrong

Amidst a “renaissance” of interest in neuropsychiatry, Seaport's executive team is taking nothing for granted.

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation.

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she will oversee BioNTech's transition from a COVID-19 vaccine maker to an “end-to-end organizational oncology powerhouse.”

Drugs developed in China have finally crossed into the mainstream, with pharma execs now eyeing these assets as novel, best-in-class options instead of me-too follow-ons.

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and pharma executives—and the general comradery in the air throughout the chaotic event.

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large.

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM and her talks with Biogen, Gilead, Novavax and more; Wegovy's higher dose induces more weight loss; AstraZeneca and Daiichi Sankyo's Dato-DXd scores its first FDA approval.

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, President Trump issued multiple executive orders that concern the industry.

On the company's Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus away from enormous takeovers to single-digit billion buy outs.